Verona Pharma plc (VRNA)
NASDAQ: VRNA · IEX Real-Time Price · USD
22.95
+0.37 (1.64%)
At close: Jul 19, 2024, 4:00 PM
23.00
+0.05 (0.22%)
Pre-market: Jul 22, 2024, 7:44 AM EDT
Verona Pharma Employees
Verona Pharma had 79 employees as of December 31, 2023. The number of employees increased by 43 or 119.44% compared to the previous year.
Employees
79
Change (1Y)
43
Growth (1Y)
119.44%
Revenue / Employee
n/a
Profits / Employee
-$802,785
Market Cap
1.86B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 79 | 43 | 119.44% |
Dec 31, 2022 | 36 | 10 | 38.46% |
Dec 31, 2021 | 26 | -1 | -3.70% |
Dec 31, 2020 | 27 | 2 | 8.00% |
Dec 31, 2019 | 25 | 10 | 66.67% |
Dec 31, 2018 | 15 | 3 | 25.00% |
Dec 31, 2017 | 12 | -3 | -20.00% |
Dec 30, 2017 | 15 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
National HealthCare | 13,123 |
Warby Parker | 3,491 |
Zai Lab | 2,175 |
NeoGenomics | 2,100 |
Alignment Healthcare | 1,536 |
RxSight | 374 |
Mirum Pharmaceuticals | 264 |
Harmony Biosciences Holdings | 246 |
VRNA News
- 24 days ago - First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product - Benzinga
- 24 days ago - Verona Pharma's inhaled COPD therapy to be priced at $2,950 per month - Reuters
- 25 days ago - US FDA approves Verona Pharma's therapy for 'smoker's lungs' - Reuters
- 25 days ago - Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine) - GlobeNewsWire
- 4 weeks ago - 5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More - Benzinga
- 2 months ago - Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS - GlobeNewsWire
- 2 months ago - Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024 - GlobeNewsWire